Topalian, Suzanne L.

Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial

Topalian, S. L., Bhatia, S., Amin, A., Kudchadkar, R. R., Sharfman, W. H., Lebbé, C., Delord, J.-P., Dunn, L. A., Shinohara, M. M., Kulikauskas, R., et al. (2020) · Journal of Clinical Oncology

Polyomavirus and related diseasesNonmelanoma Skin Cancer Studies

Cited by 280

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Stein, J. E., Lipson, E. J., Cottrell, T. R., Forde, P. M., Anders, R. A., Cimino-Mathews, A., Thompson, E. D., Allaf, M. E., Yarchoan, M., Feliciano, J., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 177

PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation

Rodić, N., Anders, R. A., Eshleman, J. R., Lin, M.-T., Xu, H., Kim, J. H., Beierl, K., Chen, S., Luber, B. S., Wang, H., et al. (2015) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 46

Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy

McMiller, T. L., Besharati, S., Yarchoan, M., Zhu, Q., Ünsal-Kaçmaz, K., Xu, K., Lee, J., Bhaijee, F., Engle, L. L., Taube, J. M., et al. (2024) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersViral-associated cancers and disorders

Cited by 16